リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Immune-related aseptic meningitis diagnosed by Cube FLAIR on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: A case report」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Immune-related aseptic meningitis diagnosed by Cube FLAIR on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: A case report

KURODA Ryo 0000-0002-7379-8899 NAKAGAWA Hiroaki 70799478 0000-0003-3830-765X UCHIDA Yasuki 90814723 0000-0002-1999-4709 NARUMIYA Keiko TSUNODA Yoko YAMAGUCHI Masafumi OKI Tatsuya HIRATSUKA Shinnosuke NAGATANI Yukihiro 80402725 0000-0002-1110-963X NAKANO Yasutaka 00362377 0000-0001-7516-8690 滋賀医科大学 DOI:10.1002/rcr2.1076

2023.01.02

概要

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), such as neurological toxicity. A 46-year-old man was diagnosed with squamous cell lung cancer. Lung cancer recurred 3 years after he experienced left segmental lung rejection. Therefore, he received atezolizumab as fourth-line chemotherapy. He experienced fever, headache, and decreased consciousness 10 days after the first dose of atezolizumab. Plain head computed tomography and cerebrospinal fluid examination showed no significant findings. Magnetic resonance imaging (MRI) with a Gadolinium (Gd)-enhanced Cube fluid-attenuated inversion recovery (FLAIR) sequence showed nodular abnormalities with contrast enhancement. Thus, aseptic meningitis caused by ICIs was suspected. His consciousness level gradually improved with glucocorticoid therapy. Moreover, most nodular abnormalities observed on cerebral MRI disappeared concurrently. Thus, Gd-enhanced Cube FLAIR sequence has the unique ability to reveal immune-related aseptic meningitis

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68. https://doi.org/10.1200/JCO.2017.77.6385

2. Blackmon JT, Viator TM, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed. 2016;1:39–45.

3. Stuby J, Herren T, Naumburger GS, Papet C, Rudiger A. Immune checkpoint inhibitors therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020;150:w20377. https://doi.org/10.4414/smw.2020.20377

4. Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Ther Adv Drug Saf. 2021;12: 20420986211004745. https://doi.org/10.1177/20420986211004745

5. Patzig M, Burke M, Bruckmann H, Fesl G. Comparison of 3D cube FLAIR with 2D FLAIR for multiple sclerosis imaging at 3 tesla. Rofo. 2014;186:484–8. https://doi.org/10.1055/s-0033-1355896

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る